目的：探讨辛伐他汀联合盐酸羟考酮控释片治疗晚期肺癌患者癌痛的有效性及安全性。方法选取2013年1月—2015年6月秦皇岛市青龙县医院收治的晚期肺癌癌痛患者80例，随机分为对照组与治疗组，每组40例。两组患者均进行化疗，在此基础上，对照组患者予以盐酸羟考酮控释片治疗，治疗组患者在对照组基础上加用辛伐他汀治疗；两组患者均连续治疗1个月。观察两组患者治疗前后暴发痛次数、视觉模拟评分法（VAS）评分、生活质量综合评定问卷（GQOL-74）评分、血清白介素6（IL-6）和肿瘤坏死因子α（TNF-α）水平、盐酸氢考酮控释片日用量及不良反应发生情况。结果治疗前两组患者暴发痛发生次数比较，差异无统计学意义（P ﹥0.05）；治疗后治疗组患者暴发痛次数少于对照组（P ﹤0.05）。治疗前两组患者 VAS 评分比较，差异无统计学意义（P ﹥0.05）；治疗后治疗组患者 VAS 评分低于对照组（P ﹤0.05）。治疗前两组患者躯体功能、心理功能、社会功能、物质生活状态、总体生活质量评分比较，差异无统计学意义（P ﹥0.05）；治疗后治疗组患者躯体功能、心理功能、社会功能、物质生活状态、总体生活质量评分高于对照组（ P ﹤0.05）。治疗前两组患者血清 IL-6、TNF-α水平比较，差异无统计学意义（ P ﹥0.05）；治疗后治疗组患者血清 IL-6、TNF-α水平低于对照组（P ﹤0.05）。治疗组患者盐酸羟考酮控释片日用量少于对照组（P ﹤0.05）。治疗组患者不良反应发生率低于对照组（P ﹤0.05）。结论辛伐他汀联合盐酸羟考酮控释片可有效减少晚期肺癌癌痛患者疼痛次数及盐酸羟考酮控释片用量，缓解患者疼痛程度，提高患者生活质量，减轻患者炎性反应，且安全性较高。%Objective To investigate the effectiveness and safety of simvastatin combined with oxycodone hydrochloride controlled - release tablets on cancerous pain of patients with advanced lung cancer. Methods From January 2013 to June 2015,a total of 80 advanced lung cancer patients complicated with cancerous pain were selected in the Hospital of Qinglong County,Qinhuangdao,and they were randomly divided into control group and treatment group,each of 40 cases. Based on chemotherapy,patients of control group received oxycodone hydrochloride controlled - release tablets,while patients of treatment group received simvastatin combined with oxycodone hydrochloride controlled - release tablets;both groups continuously treated for 1 month. Times of breakthrough pain,VAS score,GQOL-74 score,serum levels of IL-6 and TNF-α,daily dosage of oxycodone hydrochloride controlled - release tablets and incidence of adverse reactions were compared between the two groups. Results No statistically significant differences of times of breakthrough pain was found between the two groups before treatment (P ﹥ 0. 05),while times of breakthrough pain of treatment group was statistically significantly less than that of control group after treatment(P ﹤ 0. 05). No statistically significant differences of VAS score was found between the two groups before treatment (P ﹥ 0. 05),while VAS score of treatment group was statistically significantly lower than that of control group after treatment(P﹤ 0. 05 ). No statistically significant differences of physical function score,mental function score,social function score,Objective To investigate the effectiveness and safety of simvastatin combined with oxycodone hydrochloride controlled - release tablets on cancerous pain of patients with advanced lung cancer. Methods From January 2013 to June 2015,a total of 80 advanced lung cancer patients complicated with cancerous pain were selected in the Hospital of Qinglong County,Qinhuangdao,and they were randomly divided into control group and treatment group,each of 40 cases. Based on chemotherapy,patients of control group received oxycodone hydrochloride controlled - release tablets,while patients of treatment group received simvastatin combined with oxycodone hydrochloride controlled - release tablets;both groups continuously treated for 1 month. Times of breakthrough pain,VAS score,GQOL-74 score,serum levels of IL-6 and TNF-α,daily dosage of oxycodone hydrochloride controlled - release tablets and incidence of adverse reactions were compared between the two groups. Results No statistically significant differences of times of breakthrough pain was found between the two groups before treatment (P ﹥ 0. 05),while times of breakthrough pain of treatment group was statistically significantly less than that of control group after treatment(P ﹤ 0. 05). No statistically significant differences of VAS score was found between the two groups before treatment (P ﹥ 0. 05),while VAS score of treatment group was statistically significantly lower than that of control group after treatment(P﹤ 0. 05 ). No statistically significant differences of physical function score,mental function score,social function score, material living score or whole living quality score was found between the two groups before treatment(P ﹥ 0. 05),while physical function score,mental function score,social function score,material living score and whole living quality score of treatment group were statistically significantly lower than those of control group after treatment( P ﹤ 0. 05). No statistically significant differences of serum level of IL-6 or TNF-α was found between the two groups before treatment(P ﹥ 0. 05),while serum levels of IL-6 and TNF-α of treatment group were statistically significantly lower than those of control group after treatment(P ﹤ 0. 05). Daily dosage of oxycodone hydrochloride controlled - release tablets of treatment group was statistically significantly less than that of control group(P ﹤ 0. 05),while the incidence of adverse reactions of treatment group was statistically significantly lower than that of control group(P ﹤ 0. 05). Conclusion Simvastatin combined with oxycodone hydrochloride controlled - release tablets can effectively reduce the times of breakthrough pain and daily dosage of oxycodone hydrochloride controlled - release tablets, relive the pain intensity and inflammatory reaction,improve the living quality,and is safe.
展开▼
